1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,870 | 0,930 | 30.12.25 | |
| 0,000 | 0,000 | 30.12.25 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| GRAND PHARMACEUTICAL GROUP Aktie jetzt für 0€ handeln | |||||
| Mi | GRAND PHARMA (00512): CONNECTED TRANSACTION: ACQUISITION OF THE ENTIRE EQUITY INTERESTS IN HEBEI YUANDA JIUFU BIOTECHNOLOGY CO., LTD. AND BAODING JIAHE ... | 1 | HKEx | ||
| Mo | GRAND PHARMA (00512): VOLUNTARY ANNOUNCEMENT: THE WORLD'S FIRST ADRENALINE NASAL SPRAY INTRODUCED BY THE GROUP FOR THE TREATMENT OF SEVERE ALLERGIC REACTIONS ... | 1 | HKEx | ||
| 23.12.25 | GRAND PHARMA Secures Exclusive Commercialization Rights for Allergy Medicine Neffy in CN | 1 | AASTOCKS | ||
| 23.12.25 | GRAND PHARMA (00512): VOLUNTARY ANNOUNCEMENT: THE GROUP INTRODUCES THE WORLD'S FIRST ADRENALINE NASAL SPRAY FOR THE TREATMENT OF SEVERE ALLERGIC REACTIONS | 2 | HKEx | ||
| 17.12.25 | GRAND PHARMA (00512): VOLUNTARY ANNOUNCEMENT: THE GROUP'S INDEPENDENTLY DEVELOPED, BLOCKBUSTER, GLOBALLY INNOVATIVE RADIONUCLIDE-DRUG CONJUGATE, GPN01530, ... | - | HKEx | ||
| 08.12.25 | GRAND PHARMA (00512): VOLUNTARY ANNOUNCEMENT: THE PHASE II CLINICAL TRIAL IN CHINA OF THE GROUP'S CLASS 1 INNOVATIVE TRADITIONAL CHINESE MEDICINE GPN01360 ... | 1 | HKEx | ||
| 04.12.25 | GRAND PHARMA (00512): SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE 2021 AND 2022 ANNUAL REPORTS | 1 | HKEx | ||
| 10.11.25 | GRAND PHARMA (00512): VOLUNTARY ANNOUNCEMENT: GLOBAL INNOVATIVE COMBINATION PRODUCT RYALTRIS NASAL SPRAY IS APPROVED TO BE COMMERCIALIZED IN CHINA | 1 | HKEx | ||
| 09.10.25 | GRAND PHARMA (00512): VOLUNTARY ANNOUNCEMENT: THE REGISTRATION CLINICAL STUDY CONDUCTED IN CHINA OF THE GLOBAL INNOVATIVE TEMPERATURE-SENSITIVE EMBOLIC ... | - | HKEx | ||
| 24.09.25 | GRAND PHARMA (00512): INTERIM REPORT 2025 | - | HKEx | ||
| 24.09.25 | GRAND PHARMA (00512): NOTIFICATION LETTER AND REPLY FORM TO NON-REGISTERED SHAREHOLDERS - NOTICE OF PUBLICATION OF INTERIM REPORT | - | HKEx | ||
| 24.09.25 | GRAND PHARMA (00512): NOTIFICATION LETTER AND REPLY FORM TO REGISTERED SHAREHOLDERS - NOTICE OF PUBLICATION OF INTERIM REPORT | - | HKEx | ||
| 23.09.25 | GRAND PHARMA (00512): VOLUNTARY ANNOUNCEMENT: TREPROSTINIL INJECTION (20ML: 50MG) IS GRANTED A DRUG REGISTRATION CERTIFICATE | 3 | HKEx | ||
| 08.09.25 | Sirtex Medical Inc.: Sirtex Receives Expanded CE Mark Approval for SIR-Spheres Y-90 Resin Microspheres | 328 | PR Newswire | Broadened indication increases access to liver cancer treatment across Europe and CE-marked territories.
WOBURN, Mass., Sept. 8, 2025 /PRNewswire/ -- Sirtex Medical ("Sirtex"), a leading... ► Artikel lesen | |
| 08.09.25 | GRAND PHARMA (00512): VOLUNTARY ANNOUNCEMENT: NEW INDICATION OF THE GROUP'S GLOBALLY INNOVATIVE RADIOACTIVE PRODUCT SIR-SPHERES Y-90 RESIN MICROSPHERE ... | 2 | HKEx | ||
| 27.08.25 | GRAND PHARMA (00512): CONTINUING CONNECTED TRANSACTION | - | HKEx | ||
| 19.08.25 | GRAND PHARMA (00512): 2025 INTERIM RESULTS ANNOUNCEMENT | 1 | HKEx | ||
| 05.08.25 | GRAND PHARMA (00512): DATE OF BOARD MEETING | 1 | HKEx | ||
| 28.07.25 | GRAND PHARMA (00512): VOLUNTARY ANNOUNCEMENT: RESTRUCTURING OF THE SHAREHOLDING IN THE COMPANY BY THE CONTROLLING SHAREHOLDER GROUP | 2 | HKEx | ||
| 22.07.25 | GRAND PHARMA (00512): VOLUNTARY ANNOUNCEMENT: THE APPLICATION FOR THE GROUP'S GLOBAL INNOVATIVE RDC TLX591 TO JOIN AN INTERNATIONAL MULTICENTER PHASE ... | 1 | HKEx |
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FRESENIUS MEDICAL CARE | 40,760 | +0,37 % | EQS-CMS: Fresenius Medical Care AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Fresenius Medical Care AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b) der Verordnung (EU) Nr. 596/2014
Fresenius Medical Care AG: Veröffentlichung... ► Artikel lesen | |
| CARL ZEISS MEDITEC | 40,000 | -1,57 % | EILMELDUNG: Carl Zeiss Meditec-Aktie stabil - Marktbeobachter rechnen mit Bewegung. | ||
| ECKERT & ZIEGLER | 15,260 | -0,13 % | EILMELDUNG: Eckert&Ziegler-Aktie schießt nach oben - was steckt hinter der Kurs-Explosion? | ||
| MEDTRONIC | 82,47 | +0,52 % | Dividendenbekanntmachungen (26.12.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ALERUS FINANCIAL CORPORATION US01446U1034 0,21 USD 0,1782 EUR ALTRIA GROUP INC US02209S1033 1,06 USD 0,8999 EUR ARROWMARK FINANCIAL... ► Artikel lesen | |
| SERNOVA BIOTHERAPEUTICS | 0,080 | +1,27 % | Sernova Biotherapeutics Closes First Tranche of a Private Placement of Equity Financing to Support Ongoing Clinical Efforts | Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - November 13, 2025) - Sernova Biotherapeutics (TSX: SVA) (OTC: SEOVF) (FSE: PSH) ("Sernova or the Company)") a leading regenerative medicine... ► Artikel lesen | |
| FAMICORD | 6,150 | +0,82 % | EQS-News: FamiCord AG beschleunigt profitables Wachstum im dritten Quartal 2025 und stärkt Qualität und Visibilität der Umsatzentwicklung | EQS-News: FamiCord AG
/ Schlagwort(e): 9-Monatszahlen
FamiCord AG beschleunigt profitables Wachstum im dritten Quartal 2025 und stärkt Qualität und Visibilität der Umsatzentwicklung... ► Artikel lesen | |
| GERATHERM MEDICAL | 2,880 | -0,35 % | Geratherm Medical AG: Starkes Wachstum im ersten Halbjahr und operatives Break-even; KAUFEN bestätigt. | Geratherm verzeichnete im ersten Halbjahr 2025 ein starkes Wachstum: Die vergleichbaren Umsätze stiegen um 13,2 % gegenüber dem Vorjahr und sequenziell um 15,4 %. Getrieben wurde dieses Wachstum von... ► Artikel lesen | |
| PLUS THERAPEUTICS | 0,511 | 0,00 % | Plus Therapeutics Inc.: Plus Therapeutics Announces Completion of U.S. FDA Meeting on Future Clinical Development Plans for REYOBIQ in Leptomeningeal Metastases | HOUSTON, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals... ► Artikel lesen | |
| INTELLIGENT BIO SOLUTIONS | 9,530 | 0,00 % | Intelligent Bio Solutions launches $10M private placement | ||
| BETA BIONICS | 30,470 | 0,00 % | Beta Bionics, Inc.: Beta Bionics Reports Third Quarter 2025 Financial Results and Raises Full Year 2025 Guidance | IRVINE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial... ► Artikel lesen | |
| GENEDX | 130,06 | +1,61 % | GeneDx to Participate in Upcoming Investor Conferences | GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in upcoming investor conferences:
Stifel... ► Artikel lesen | |
| HEARTFLOW | 29,150 | -3,51 % | Heartflow, Inc.: Heartflow FFRCT Analysis Delivers Prognostic Power and Significant Cost Savings in New Analyses of Over 90,000 Patients with Coronary Artery Disease | Lesion-specific FFRCT predicts individual cardiovascular outcomes and delivers greater-than-modeled cost savings for real-world population in FISH&CHIPS analyses from England's National Health ServiceMOUNTAIN... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 19,760 | +2,70 % | Alignment Healthcare Reports Third Quarter 2025 Results, Surpasses High-End of Guidance Across All Key Metrics | Reports Q3 revenue of $993.7 million, up 43.5% year-over-yearBeats high end of third quarter guidance and raises full-year outlook across all key metrics: membership, revenue, adjusted gross profit... ► Artikel lesen | |
| AVEANNA HEALTHCARE | 8,170 | -2,62 % | Aveanna Healthcare Holdings, Inc: Aveanna Healthcare Holdings Announces Third Quarter Financial Results and Revised 2025 Outlook | Third Quarter Revenue was $621.9 million, a 22.2% increase over the prior year periodThird Quarter Net income was $14.1 million compared to Net loss of $42.8 million for the prior year periodAdjusted... ► Artikel lesen | |
| SIGHT SCIENCES | 7,930 | -0,88 % | Sight Sciences, Inc.: Sight Sciences Appoints Ali Bauerlein as Chief Operating Officer and Jim Rodberg as Chief Financial Officer | MENLO PARK, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences, or the Company), an eyecare technology company focused on developing and commercializing... ► Artikel lesen |
GRAND PHARMACEUTICAL GROUP LTD gehört der Branche Gesundheitswesen an. Der aktuelle Kurs liegt bei 0,910 Euro und damit +14,47 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GRAND PHARMACEUTICAL GROUP LTD finden Sie auf Wallstreet Online.